Marshall Wace, LLP Enlivex Therapeutics Ltd. Transaction History

Marshall Wace, LLP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$4.92 - $6.66 $31,419 - $42,530	-6,386 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$5.81 - $9.73 $37,102 - $62,135	6,386 New	6,386 $39,000
Q2 2021 Aug 13, 2021	SELL	$8.61 - $12.1 $291,784 - $410,056	-33,889 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$9.26 - $24.0 $313,812 - $813,336	33,889 New	33,889 $376,000

2.1M

16.1K

3.4K

Ticker ENLV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 18,403,200
Market Cap $28.9M
Description
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.